Led the March 2026 private placement of common stock and pre-funded warrants at $2.25 per share, with accompanying redeemable warrants.
| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Steve Ledger
Also a director
Chief Executive Officer and Class II Director
|
66 | Not stated | Not stated | $637,500 | |
|
Gregory S. Curhan
Chief Financial Officer
|
64 |
Since 2024
2 years
|
Not stated | Not reported | |
|
Randall Moreadith, M.D., Ph.D.
Chief Scientific Officer
Title from the Form 4 dated May 21, 2026
|
72 | Not stated | 2010 | $563,200 | |
|
Srini Tenjarla, Ph.D.
SVP, CMC & Formulation
Title from the Form 4 dated May 21, 2026
|
63 | Not stated | Not stated | $527,400 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 27, 2026 · updated by the 8-K of Jul 22, 2026
| Director | Age | On board | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|
|
Gregory H. Bailey, M.D.
Board chair
|
70 |
2018
8 years
|
Compensation
|
BioHaven Ltd., Manx Financial Group, plc, SalvaRx Group, plc | $82,616 | |
|
Balkrishan “Simba” Gill
Board chair
|
62 |
2024
2 years
|
None stated | Foghorn Therapeutics | Not stated | |
|
Steve Ledger
CEO
|
66 |
2022
4 years
|
None stated | None stated | Paid as CEO | |
|
Richard Marshall, CBE, M.D., Ph.D.
|
59 |
2024
2 years
|
Nominating and Corporate Governance
|
None stated | $82,616 | |
|
Jay Venkatesan, M.D.
|
54 |
2025
1 year
|
Audit
Nominating and Corporate Governance · Chair
|
Elicio Therapeutics, Inc. | $222,160 | |
|
Stephen Brannan, M.D.
|
69 |
2025
1 year
|
Audit
Compensation
|
None stated | $255,375 | |
|
Karen J. Wilson
|
63 |
2025
1 year
|
Audit · Chair
Compensation · Chair
Nominating and Corporate Governance
|
Connect Biopharma Holdings Limited, Elicio Therapeutics, Inc. | $240,105 | |
|
Farrell Simon
Joined Jul 22, 2026
|
- | - |
Audit Committee
Compensation Committee
|
- | - |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
Led the March 2026 private placement of common stock and pre-funded warrants at $2.25 per share, with accompanying redeemable warrants.
Unsecured convertible note under which Dr. Bailey agreed to make available borrowings to the Company.
Purchased shares of Series A Convertible Preferred Stock in a private placement at $5.18 per share.
Participated as an investor in the April 2025 private placement of Series A Convertible Preferred Stock.
Loading...